Research Paper Volume 12, Issue 7 pp 5792—5811
Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML
Figure 1. Genetic landscape of elderly AML patients. (A) Heatmap showing associations between different gene mutations. Each column represents one patient. (B) Gene mutations in 125 AML patients ≥ 60 years of age at primary diagnosis. Bar chart showing the 13 most commonly mutated genes in elderly AML patients aged 60-66, 67-74, and 75-86 years at primary diagnosis.